Peter O'Dwyer is a GI oncologist who co-leads ECOG-ACRIN, one of the NCI's national trial networks.
Peter O'Dwyer is Group Co-Chair of the ECOG-ACRIN Cancer Research Group and Professor of Medicine at the University of Pennsylvania, within the Abramson Cancer Center. A gastrointestinal medical oncologist with a background in pharmacology and early drug development, he co-chairs ECOG-ACRIN with Mitchell Schnall and directs the Penn Developmental Therapeutics Program. His papers include the Eastern Cooperative Oncology Group study E3200 of bevacizumab combined with FOLFOX4 for previously treated metastatic colorectal cancer and a New England Journal of Medicine review of the status of etoposide as an active anticancer drug. His work spans colorectal cancer, pancreatic ductal adenocarcinoma and cooperative group trials.
| Title | Journal | Year |
|---|---|---|
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Journal of Clinical Oncology | 2023 |
| Etoposide (VP-16-213). Current status of an active anticancer drug | New England Journal of Medicine | 1985 |
Shares ECOG-ACRIN Cancer Research Group, Abramson Cancer Center, University of Pennsylvania.
Shares NCI-MATCH (EAY131), ECOG-ACRIN Cancer Research Group.
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/